Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 ...

President Abdel Fattah El-Sisi highlighted on Sunday 20/10/2024 Egypt's program with the International Monetary Fund (IMF), noting that the country may "review the situation" with global lender if the ...